This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-22 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
==== Gel electrophoresis under denaturing conditions ==== Denaturing gel electrophoresis, commonly performed using SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), involves treating proteins with SDS, a detergent that denatures proteins and imparts a uniform negative charge. This allows proteins to be separated solely based on their molecular weight, providing a clear picture of the protein composition of a sample.
== See also == Marooned off Vesta, a short story by Isaac Asimov first published in 1939 Vega (disambiguation) Vespa (disambiguation) Vestal (disambiguation) Vestas, a Danish manufacturer of wind turbines
=== Disease association === LNPEP has five common (>1% in GnomAD) missense variants of which the most common rs2303138, leading to an amino acid substitution (Ala763Thr), has been related to psoriasis and ankylosing spondylitis risk. IRAP's precise role in these conditions remains unknown but given its involvement in activation of adaptive and innate immune responses, the renin-angiotensin system (RAS) and glucose metabolism, these genetic variants may have pleiotropic impacts on immune, circulatory, and metabolic systems. Two other common missense variants rs41276279 (p. Val373Ile) and rs11746232 (p. Ile963Val) moderately correlate with LNPEP gene expression levels (reference to gtexportal.org) but have not been linked to disease so far.
Sources: en.wikipedia.org
== Function == As its name suggests, NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons) and is critical for the survival and maintenance of sympathetic and sensory neurons as they undergo apoptosis in its absence. However, several recent studies suggest that NGF is also involved in pathways besides those regulating the life cycle of neurons.
== Chemistry == Ketoconazole is a synthetic imidazole. It is a nonsteroidal compound. It is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole). Levoketoconazole is under development for potential clinical use as a steroidogenesis inhibitor with better tolerability and less toxicity than ketoconazole. Other steroidogenesis inhibitors besides ketoconazole and levoketoconazole include the nonsteroidal compound aminoglutethimide and the steroidal compound abiraterone acetate.
=== Hosting === In addition to acting, Hart has also hosted various ceremonies. Hart first hosted the 2011 BET Awards. Hart then hosted the 2012 MTV Video Music Awards, after his longtime friend Judd Apatow, the director who gave him his first big on-screen break in the TV series Undeclared, recommended him for the position. Hart hoped this would project him into a side career as an emcee, stating: "Hopefully after MTV, of course we're talking Emmys, Oscars, whatever." From 2013–2015, he hosted three episodes of Saturday Night Live. In 2015, Hart hosted the Comedy Central Roast of Justin Bieber. In 2016, Hart co-hosted the 2016 MTV Movie Awards with Dwayne Johnson. In September 2018 Hart hosted HQ Trivia with Scott Rogowsky and gave away $100,000 to one person. On December 4, 2018, Hart was announced as the host of the 2019 Academy Awards. Two days later, however, he withdrew from hosting duties in the wake of backlash against him over several homophobic tweets he had posted between 2010 and 2011. He characterized the protest as unconstructive and argued: "If you don't believe people change, grow as they get older, I don't know what to tell you." On December 7, he tweeted an apology to the LGBTQ community following criticism for not issuing one the previous day.
2008–09 - Michael "Michi" Mueller - Puma Ocean Racing 2011–12 - David "Dave" Swete - Team Sanya 2014–15 - Sophie Ciszek - Team SCA 2017–18 - Bleddyn Mon - Turn the Tide on Plastic 2023–23 - Will Harris - Team Malizia
Sources: en.wikipedia.org
=== Hezbollah and Hamas === At a 22 July 2006 demonstration (and later in a Socialist Worker op-ed), Galloway stated that "Hizbollah is not and has never been a terrorist organisation. It is the legitimate national resistance movement of Lebanon". He further said: "The invasion of Lebanon by Israel, for that's what it is, is a monstrous injustice. I side with the resistance to that injustice. Hizbollah is leading that resistance. ... I glorify the Hizbollah national resistance movement, and I glorify the leader of Hizbollah, Sayyed Hassan Nasrallah". In 2009, Galloway received a Palestinian passport from Hamas leader Ismail Haniyeh. Hamas is designated as a terrorist organisation by Israel, the European Union, the United Kingdom, and the United States. He was denied entry into Canada on national security grounds, with Alykhan Velshi, then a spokesman for Jason Kenney, Canada's immigration minister, commenting: "We're going to uphold the law, not give special treatment to this infandous street-corner Cromwell who actually brags about giving 'financial support' to Hamas, a terrorist organisation banned in Canada." After a 2010 investigation into the actions of Velshi and other staffers in Kenney's office and into decisions made by bureaucrats prior to Galloway's visit, Justice Richard Mosley ruled that the government's decision to ban Galloway was politically motivated. A week after Mosley's ruling, Galloway travelled to Canada.
Although widespread metal tolerance seems to be the norm for ectomycorrhizal fungi, it has been suggested that a few fungi such as Pisolithus tinctorius, P. albus and species in the genus Suillus can become adapted to high levels of Al, Zn, Cd and Cu. Suillus luteus and S. bovinus are good examples, with known ecotypes adapted to Zn, Cd and Cu.
=== Social sciences === Finance: a retirement fund will decay exponentially being subject to discrete payout amounts, usually monthly, and an input subject to a continuous interest rate. A differential equation dA/dt = input − output can be written and solved to find the time to reach any amount A, remaining in the fund. In simple glottochronology, the (debatable) assumption of a constant decay rate in languages allows one to estimate the age of single languages. (To compute the time of split between two languages requires additional assumptions, independent of exponential decay).
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.